RCS - Theracryf PLC - World Mental Health Day & Q4 Conference Schedule

TheracryfAnnouncement

10/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251010:nRSJ8270Ca&default-theme=true

RNS Number : 8270C  Theracryf PLC  10 October 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Marking World Mental Health Day and Q4 Conference Schedule Update

 

Alderley Park, 10 October 2025 - TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on brain disorders, notes that today is
World Mental Health Day and also shares its conference schedule for Q4 2025.

 

World Mental Health Day

10 October is World Mental Health Day (https://wmhdofficial.com/) , aiming to
raise awareness of mental health issues around the world and to mobilize
efforts in support of mental health. Globally, more than 1 billion people
live with a mental health condition*, with anxiety and depression being the
most common, according to the World Health Organization.

 

TheraCryf is honoured to be contributing to the potential treatment of mental
disorders such as anxiety and addictive behaviour through its lead Ox-1
programme, a class-leading orexin-1 antagonist,  targeting binge eating
disorder and other substance use disorders.

 

TheraCryf's Chief Operating Officer, Dr Helen Kuhlman, discusses the potential
of orexin-based treatments for addictive behaviours in her article 'The
Promise of Orexin-1 Antagonists in Addiction Treatment', in the most recent
edition of European Biopharmaceutical Review
(https://www.calameo.com/read/006113385ec12c4787de3?page=1) .

 

*World Mental Health Today Report, September 2025

 

Q4 Conference Schedule

The TheraCryf leadership team will also be attending the following industry
and investor conferences and events during Q4.

 

BioSeed North, 21 October 2025, Manchester

BioEurope, 3-5 November 2025, Vienna

ShareSoc Growth Company Seminar, 13 November 2025, London

Mello London, 18-19 November 2025, London

London Life Sciences Week & Jefferies Global Healthcare Conference, 17-21
November 2025, London

 

Dr Huw Jones, CEO of TheraCryf, said:

"As we mark World Mental Health Day, we are very much aware of the impact
mental health conditions have on quality of life for sufferers and their
families. We are on track with our work to enable our orexin-1 blocker to be
used in clinical trials in under a year from now. The promise of these
potential medicines is made very clear in the recent European Biopharma Review
article and we look forward to reminding the industry and investors of the
opportunity and plans for our lead programme during the upcoming conference
season."

 

-Ends-

Enquiries

 TheraCryf plc                                       +44 (0)1625 315 090

 Dr Huw Jones, CEO                                   enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, COO

 Singer Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7496 3000
 Phil Davies / Oliver Platts / Patrick Weaver

 Turner Pope Investments (Joint Broker)              +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Vigo Consulting                                     +44 (0)20 7390 0230

 Rozi Morris/ Melanie Toyne Sewell                   theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma*
and neurodevelopmental disorders [*orphan indication].

 

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know-how for
programmes from companies such as Shire (now Takeda).

 

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

 

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUKVRRVOURRUA